Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 131


Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.

Pitter KL, Galbán CJ, Galbán S, Tehrani OS, Li F, Charles N, Bradbury MS, Becher OJ, Chenevert TL, Rehemtulla A, Ross BD, Holland EC, Hambardzumyan D.

PLoS One. 2011 Jan 18;6(1):e14545. doi: 10.1371/journal.pone.0014545. Erratum in: PLoS One. 2011;6(1). doi: 10.1371/annotation/66641ad6-afb9-4d3c-ade6-73fcd5aab061. Saeed-Tehrani, Omid [corrected to Tehrani, Omid Saeed].


Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N.

Mol Cancer Ther. 2010 Apr;9(4):963-75. doi: 10.1158/1535-7163.MCT-09-0763. Epub 2010 Apr 6.


Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS.

Cancer Res. 2006 Aug 15;66(16):7864-9.


Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.

Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H.

Clin Exp Pharmacol Physiol. 2013 Jan;40(1):13-21. doi: 10.1111/1440-1681.12026.


Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL.

PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008.


PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.

Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O.

Br J Cancer. 2013 Sep 17;109(6):1586-92. doi: 10.1038/bjc.2013.505. Epub 2013 Aug 29.


Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.

Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX.

Mol Cancer Ther. 2013 Aug;12(8):1665-75. doi: 10.1158/1535-7163.MCT-13-0159. Epub 2013 May 20.


Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.

Liu D, Hou P, Liu Z, Wu G, Xing M.

Cancer Res. 2009 Sep 15;69(18):7311-9. doi: 10.1158/0008-5472.CAN-09-1077. Epub 2009 Aug 25. Erratum in: Cancer Res. 2009 Oct 15;69(20):8216.


A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.

Yang S, Xiao X, Meng X, Leslie KK.

PLoS One. 2011;6(10):e26343. doi: 10.1371/journal.pone.0026343. Epub 2011 Oct 19.


Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A.

Cancer Res. 2002 Sep 1;62(17):5027-34.


Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9. Epub 2001 Aug 14.


Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.

Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR.

Clin Cancer Res. 2011 Dec 1;17(23):7359-72. doi: 10.1158/1078-0432.CCR-11-1388. Epub 2011 Sep 8.


EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.

Li T, Yang Y, Li X, Xu C, Meng L.

Mol Cell Biochem. 2012 Feb;361(1-2):19-29. doi: 10.1007/s11010-011-1082-0. Epub 2011 Sep 28.


PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer.

Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR.

Am J Pathol. 2012 Mar;180(3):1017-27. doi: 10.1016/j.ajpath.2011.11.021. Epub 2011 Dec 28.


Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells.

Pan Y, Weinman EJ, Dai JL.

Breast Cancer Res. 2008;10(1):R5. doi: 10.1186/bcr1846. Epub 2008 Jan 11.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk